伴18外显子G719X突变的多发转移晚期肺腺癌一线TKI治疗1例报道

Multiple metastatic advanced lung adenocarcinoma with 18 exon G719X mutation:first-line TKI treatment 1 case report

肺癌是全球癌症相关死亡的主要原因。高达85%的肺癌患者病理类型是非小细胞肺癌,大多数患者在首次诊断时已为晚期。靶向治疗在晚期非小细胞肺癌的治疗中发挥着重要作用。表皮生长因子受体(EGFR)突变是酪氨酸激酶抑制剂治疗敏感性的预测标志。本文介绍1例EGFR exon18 G719X突变的多发转移肺腺癌患者,在使用阿法替尼治疗后出现快速耐药而寻求国际多学科会诊。经肿瘤内科、呼吸科、影像科等多学科会诊后,建议继续使用当前治疗,密切观察患者病情变化,根据病情变化及时调整治疗方案。

Lung cancer is the leading cause of cancer-related death worldwide.Up to 85%of lung cancer patients are non-small cell lung cancer(NSCLC),and most patients are in advanced stage at the time of initial diagnosis.Targeted therapy plays an important role in the treatment of advanced NSCLC.Epidermal growth factor receptor(EGFR)mutations are predictive markers of therapeutic sensitivity to tyrosine kinase inhibitors.This article described the treatment process of a patient with multiple metastatic lung adenocarcinoma with EGFR exon 18 G719X mutation,who sought an international multidisciplinary consultation after developing rapid resistance to afatinib treatment.After multi-disciplinary consultation in medical oncology,respiratory,imaging,etc.,it was recommended to continue to use the current treatment,closely observe the changes in the patient′s condition,and adjust the treatment plan in time according to the changes in the condition.